| 產(chǎn)品編號(hào) | bs-7362R |
| 英文名稱 | Rabbit Anti-Melan A antibody |
| 中文名稱 | 黑色素瘤相關(guān)抗原/黑色素-A抗體 |
| 別 名 | MAR1_HUMAN; Melanoma antigen recognized by T-cells 1; MLANA; MART1; Antigen LB39-AA; Antigen SK29-AA; Protein Melan-A; |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) t-淋巴細(xì)胞 |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human,Mouse (predicted: Rat) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 13kDa |
| 細(xì)胞定位 | 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from mouse Melan A: 1-80/113 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Melanoma-associated antigens recognized by cytotoxic T lymphocytes (CTL) have been grouped into three categories: melanocyte differentiation antigens, cancer/testis-specific antigens and mutated or aberrantly expressed antigens. Many of these antigens consist of peptides that are presented to T cells by HLA molecules; they represent potential targets for cancer immunotherapy. Melan-A (also designated MART-1) is a melanocyte differentiation antigen that is specific to melanomas, melanocyte cell lines and retina. Melan-A peptide is recognized by most HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes in patients with melanoma. Antimelanoma cytotoxic T lymphocytes can be generated with a Melan-A peptide, implicating Melan-A as a potential candidate for antigen-specific immunotherapy in melanoma patients. Function: Involved in melanosome biogenesis by ensuring the stability of GPR143. Plays a vital role in the expression, stability, trafficking, and processing of melanocyte protein PMEL, which is critical to the formation of stage II melanosomes. Subunit: Interacts with PMEL. Interacts with GPR143. Subcellular Location: Endoplasmic reticulum membrane. Golgi apparatus. Golgi apparatus > trans-Golgi network membrane. Melanosome. Also found in small vesicles and tubules dispersed over the entire cytoplasm. A small fraction of the protein is inserted into the membrane in an inverted orientation. Inversion of membrane topology results in the relocalization of the protein from a predominant Endoplasmic reticulum membrane. Golgi apparatus. Golgi apparatus > trans-Golgi network membrane. Melanosome. Also found in small vesicles and tubules dispersed over the entire cytoplasm. A small fraction of the protein is inserted into the membrane in an inverted orientation. Inversion of membrane topology results in the relocalization of the protein from a predominant Golgi/post-Golgi area to the endoplasmic reticulum. Melanoma cells expressing the protein with an inverted membrane topology are more effectively recognized by specific cytolytic T-lymphocytes than those expressing the protein in its native membrane orientation. Tissue Specificity: Expression is restricted to melanoma and melanocyte cell lines and retina. Post-translational modifications: Acylated. SWISS: Q2TA50 Gene ID: 77836 Database links: Entrez Gene: 77836 Mouse |
| 產(chǎn)品圖片 |
Protein: disease lung in mouse lysate;
Primary: rabbit Anti-Melan A (bs-7362R) at 1:300;
Secondary: HRP conjugated Goat-Anti-rabbit IgG(bs-0295G-HRP) at 1: 5000;
Predicted band size: 26 kD
Observed band size: 26 kD
Tissue/cell: human melanoma tissue; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-Melan A Polyclonal Antibody, Unconjugated(bs-7362R) 1:500, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining
|
